Thomas J. Connors

Thomas J. Connors

Auto-generated profile, based on publicly available information

Thomas J. Connors

Department of Pediatrics, Columbia University Irving Medical Center, New York, USA

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 February 2018 in Immunity
Verified
Journal Article
Closed access
BKBrahma V. Kumar
Brahma V. Kumar
TCThomas J. Connors
Thomas J. Connors
DFDonna L. Farber
Donna L. Farber

5 November 2020 in Nature Immunology
Verified
Journal Article
Open access
PDF file
SWStuart P. Weisberg
Stuart P. Weisberg
TCThomas J. Connors
Thomas J. Connors
YZYun Zhu
Yun Zhu
MBMatthew R. Baldwin
Matthew R. Baldwin
WLWen-Hsuan Lin
Wen-Hsuan Lin
DFDonna L. Farber
Donna L. Farber
Clinical manifestations of COVID-19 caused by the new coronavirus SARS-CoV-2 are associated with age1,2. Adults develop respiratory symptoms, which can progress to acute respiratory distress syndrome (ARDS) in the most severe form, while children are largely spared from respiratory illness but can develop a life-threatening multisystem inflammatory syndrome (MIS-C)3,4,5. Here, we show distinct antibody responses in children and adults after SARS-CoV-2 infection. Adult COVID-19 cohorts had anti-spike (S) IgG, IgM and IgA antibodies, as well as anti-nucleocapsid (N) IgG antibody, while children with and without MIS-C had reduced breadth of anti-SARS-CoV-2-specific antibodies, predominantly generating IgG antibodies specific for the S protein but not the N protein. Moreover, children with and without MIS-C had reduced neutralizing activity as compared to both adult COVID-19 cohorts, indicating a reduced protective serological response. These results suggest a distinct infection course and immune response in children independent of whether they develop MIS-C, with implications for developing age-targeted strategies for testing and protecting the population.

1 April 2021 in Immunity
Verified
Journal Article
Closed access
PSPeter A. Szabo
Peter A. Szabo
PDPranay Dogra
Pranay Dogra
JGJoshua I. Gray
Joshua I. Gray
SWSteven B. Wells
Steven B. Wells
TCThomas J. Connors
Thomas J. Connors
DFDonna L. Farber
Donna L. Farber

1 March 2017 in Immunity
Verified
Journal Article
Closed access
TGTomer Granot
Tomer Granot
TSTakashi Senda
Takashi Senda
DCDustin J. Carpenter
Dustin J. Carpenter
NMNobuhide Matsuoka
Nobuhide Matsuoka
JWJoshua Weiner
Joshua Weiner
DFDonna L. Farber
Donna L. Farber

22 March 2019 in Science Immunology
Verified
Journal Article
Closed access
PDF file
MSMark E. Snyder
Mark E. Snyder
MFMichael O. Finlayson
Michael O. Finlayson
TCThomas J. Connors
Thomas J. Connors
PDPranay Dogra
Pranay Dogra
TSTakashi Senda
Takashi Senda
DFDonna L. Farber
Donna L. Farber
Tissue-resident memory T cells (TRM) maintain immunity in diverse sites as determined in mouse models, whereas their establishment and role in human tissues have been difficult to assess. Here, we investigated human lung TRM generation, maintenance, and function in airway samples obtained longitudinally from human leukocyte antigen (HLA)–disparate lung transplant recipients, where donor and recipient T cells could be localized and tracked over time. Donor T cells persist specifically in the lungs (and not blood) of transplant recipients and express high levels of TRM signature markers including CD69, CD103, and CD49a, whereas lung-infiltrating recipient T cells gradually acquire TRM phenotypes over months in vivo. Single-cell transcriptome profiling of airway T cells reveals that donor T cells comprise two TRM-like subsets with varying levels of expression of TRM-associated genes, whereas recipient T cells comprised non-TRM and similar TRM-like subpopulations, suggesting de novo TRM generation. Transplant recipients exhibiting higher frequencies of persisting donor TRM experienced fewer adverse clinical events such as primary graft dysfunction and acute cellular rejection compared with recipients with low donor TRM persistence, suggesting that monitoring TRM dynamics could be clinically informative. Together, our results provide spatial and temporal insights into how human TRM develop, function, persist, and affect tissue integrity within the complexities of lung transplantation.

19 November 2021 in Science Immunology
Verified
Journal Article
Open access
MPMaya M.L. Poon
Maya M.L. Poon
KRKsenia Rybkina
Ksenia Rybkina
YKYu Kato
Yu Kato
MKMasaru Kubota
Masaru Kubota
RMRei Matsumoto
Rei Matsumoto
DFDonna L. Farber
Donna L. Farber
SARS-CoV-2–specific memory cells persist in multiple sites months after infection, particularly in lungs and associated lymph nodes.